Oleg Movchan Sells 2,771 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now owns 526,702 shares in the company, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Enfusion Stock Performance

Shares of ENFN opened at $9.97 on Friday. The stock has a 50 day moving average price of $10.11 and a 200 day moving average price of $9.20. Enfusion, Inc. has a one year low of $7.52 and a one year high of $11.38. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of 249.31, a PEG ratio of 3.98 and a beta of 0.95.

Analyst Ratings Changes

A number of analysts have recently commented on ENFN shares. Piper Sandler boosted their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus upped their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $10.25.

Institutional Investors Weigh In On Enfusion

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its stake in Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock valued at $9,770,000 after acquiring an additional 70,367 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after purchasing an additional 61,032 shares during the last quarter. State Street Corp grew its position in shares of Enfusion by 2.3% in the third quarter. State Street Corp now owns 952,895 shares of the company’s stock valued at $9,043,000 after purchasing an additional 21,729 shares in the last quarter. Impax Asset Management Group plc increased its holdings in shares of Enfusion by 25.4% in the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after purchasing an additional 136,948 shares during the last quarter. Finally, Scalar Gauge Management LLC lifted its position in Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after buying an additional 110,000 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.